JW Pharmaceutical(001060), buoyed by strong sales of major prescription drugs (ETC), increased both revenue and operating profit in the second quarter of this year. The Livalo family, along with Ferrinject and Truepass, continued their growth, driving results.
JW Pharmaceutical disclosed on the 11th that, on a separate basis, second-quarter revenue was 220.3 billion won and operating profit was 33.7 billion won. Compared with a year earlier, revenue rose 16.1% and operating profit increased 32.7%. The operating margin was tallied at 15.3%. Net profit swung to a gain of 27.1 billion won.
Revenue in the ETC institutional sector was 183.2 billion won, up 17.8%. Sales of the dyslipidemia treatment "Livalozet " were 30.5 billion won, up 20%, and revenue for the Livalo family—including Livalo, Livalozet , Livalo V, Livalo High, and Livalo Pheno—was 53.2 billion won, up 12.3%.
Other key products also showed notable growth. Sales of the high-dose iron injection "Ferinject" were 8.1 billion won, up 90.1%, and the benign prostatic hyperplasia treatment "Truepass" rose 50.6% to 4 billion won.
Revenue in the infusion institutional sector was 72.4 billion won, up 13.7%. Over-the-counter (OTC) sales also increased 19.9% to 14.7 billion won, while revenue for the Friends product line rose 46% to 5.6 billion won.
A JW Pharmaceutical official said, "The overall business is maintaining stable growth centered on original prescription drugs," adding, "Based on a solid revenue foundation, we will expand investment in research and development (R&D) and secure future growth engines."